General

India: Takeda Launches Enzyme Replacement Therapy for ‘Lysosomal Storage Disorders’ (LSD)

NewsGram Desk

Expanding its portfolio of rare disease therapies in India, global bio-pharmaceutical company Takeda on Monday announced launch of the enzyme replacement therapy for 'lysosomal storage disorders' (LSD).

"Under 'lysosomal storage disorders', India has been recording prevalence of Hunter Syndrome, Gaucher Disease and Fabry Disease. To address these, Takeda brings to the market Idursulfase for Hunter Syndrome, Velaglucerase Alpha for Gaucher Disease and Agalsidase Alfa for Fabry Disease," the company said in a statement.

Fabry disease interferes with the body's ability to break down a specific fatty substance (globotriaosylceramide or Gb3). Over 8,000-10,000 people worldwide have been affected by the disease.

Expanding its portfolio of rare disease therapies in India, global bio-pharmaceutical company Takeda on Monday announced launch of the enzyme replacement therapy for 'lysosomal storage disorders' (LSD). Pixabay

Hunter Syndrome is a serious genetic disorder that interferes with the body's ability to break down specific mucopolysaccharides, also known as glycosaminoglycans or GAGs. It primarily affects males.

Gaucher is a rare inherited metabolic condition that affects approximately one in 100,000 people. Patients with type-1 Gaucher disease may experience varying symptoms and degrees of disease severity, making it difficult to diagnose. (IANS)

Hegseth: US committed to defense of Pacific territories against China

Things you can do if your pet is frightened by fireworks

China Irked on India's Involvement in Dalai Lama succession, Issues warning

How Longwala reimagined rural governance

Flexport CEO criticizes PM Modi’s GST Claim, Calls It “Useless Paperwork”